A multicenter, real-world study of prostatitis treated with Qianliexin capsules

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057560

Enrollment

Unknown

Registered

2022-03-15

Start date

2021-09-09

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic prostatitis

Interventions

All samples meeting the inclusion criteria:Taking Qianliexin capsules

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-50 years (including 18 and 50 years); 2. Patients who meet the diagnostic criteria of chronic prostatitis in Western medicine and syndrome differentiation criteria of blood stasis and dampness-heat in Chinese medicine; 3. The patients voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with serious primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic systems; 2. Accompanied by mental disease or severe neurosis; 3. Stones or tumors in the urinary system.

Design outcomes

Primary

Measure	Time frame
NIH-Chronic Prostatitis Symptom Index response rate;NIH-Chronic Prostatitis Symptom Index total score;	—

Secondary

Measure	Time frame
NIH-CPSI Single symptom score;Liver and kidney function;Adverse Events;Drug economic evaluation;	—

Countries

China

Contacts

Public ContactBin Wang

Dongzhimen Hospital, Beijing University of Chinese Medicine

dayiwangbin@sina.com+86 13911103953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026